In Silico Clinical Trials - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

In-silico clinical trial market size in 2026 is estimated at USD 4.16 billion, growing from 2025 value of USD 3.87 billion with 2031 projections showing USD 5.93 billion, growing at 7.41% CAGR over 2026-2031. This report is Segmented by Therapeutic Area (Oncology, Infectious Disease, Cardiology, Neurology, and More), Industry (Pharmaceutical, Medical Devices, and CROs), Phase (Phase I, Phase II, Phase III, and Phase IV & Post-Market), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global In Silico Clinical Trials Market Trends and Insights

Regulatory Endorsement of In-Silico Evidence

The United States Food and Drug Administration recently broadened its computational modeling guidance, confirming that verified virtual evidence can support device 510(k) and biologic IND filings. European lawmakers echo the approach through the European Health Data Space Regulation, which enables cross-border data flows essential for large-scale virtual cohorts. Early applicants that submitted AI-generated dossiers reported shorter review cycles, signalling that regulators view model-based submissions as resource-efficient. Industry now invests in end-to-end validation workflows anchored in ASME V&V 40 principles, providing a repeatable route to credibility. As multiple jurisdictions converge on harmonised rules, sponsors gain confidence to allocate larger budgets to in-silico trial design.

Rising R&D Cost Pressure Across Pharma and Med-Tech

Total R&D expense required to bring a single novel drug to market has climbed above USD 1 billion, a 14-fold increase versus the 1960s. Companies respond by redirecting funds toward digital twin platforms that can simulate dose-response curves across thousands of virtual patients, cutting wet-lab screening cycles by up to 70%. Large pharma-device partnerships such as Charles River Laboratories and Sanofi demonstrate cost avoidance through virtual control groups, reducing animal use while maintaining statistical power. Medical-device manufacturers follow suit because computational stress testing eliminates multiple prototype iterations. Combined, these economics add more than a full percentage point to operating margins for early adopters.

Limited Standardisation of Modelling Methodologies

Regulatory agencies encourage verification but have yet to agree on a single global framework. Sponsors therefore build parallel validation packages for the FDA, EMA and Japan’s PMDA, inflating timelines. While ASME V&V 40 and the TRIPOD+AI guideline provide structure, implementation varies by therapeutic area, forcing bespoke parameter checks for each filing. Smaller biotechnology firms find the resource burden heavy, which slows broader market penetration until harmonised assessment tools mature.

Other drivers and restraints analyzed in the detailed report include:

• Pandemic-Induced Digital Transformation in Clinical Development
• Accelerating Adoption of Precision Medicine and Digital Twins
• Growing HPC and Cloud Computing Accessibility
• Sustainability Mandates and 3R Animal-Reduction Policies
• Data Privacy and Interoperability Challenges

Segment Analysis

Oncology held 25.12% of the in-silico clinical trial market in 2025, reflecting its dependence on multi-drug regimens that benefit from dose-optimisation in silico. The segment gains additional momentum from tumour genetic heterogeneity, which requires large synthetic cohorts to achieve statistical power. The in-silico clinical trial market size for oncology is projected to reach USD 1.71 billion by 2031, tracking a 6.78% CAGR as digital twins guide adaptive designs. Neurology is the fastest-growing discipline at a 15.11% CAGR, driven by Stanford’s visual-cortex digital twin that enables unlimited virtual experimentation. Beyond these two areas, infectious-disease models use AI to repurpose antivirals quickly, cardiology twins refine device implantation strategies, and metabolic-disease avatars personalise insulin and GLP-1 dosing.

Demand for virtual oncology stacks encourages CROs to develop oncology-specific libraries of immuno-genomic profiles, reducing time to model calibration. Neurology providers leverage data from brain-organoid experiments to increase biological fidelity, making virtual neuro-pharmacology more predictive. Together, these two therapeutic areas set the pace for future regulatory templates and commercial reimbursement frameworks.

Complete Report Scope:

• By Therapeutic Area
  • Oncology
  • Infectious Disease
  • Cardiology
  • Neurology
  • Diabetes
  • Other Therapeutic Areas
• By Industry
  • Pharmaceutical
  • Medical Devices
  • Contract Research Organisations (CROs)
• By Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV & Post-Market
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 46.21% share in 2025 thanks to clear FDA guidance, extensive venture capital and strong supercomputing infrastructure. Recursion, Tempus and Insilico Medicine each raised nine-figure rounds to scale drug-discovery digital twins, reflecting investor confidence. The agency’s plan to discontinue animal tests for certain biologics accelerates local demand, and academic hubs from Boston to the Bay Area serve as technology incubators. Canada supports the ecosystem with national AI superclusters that subsidise compute credits for health-tech startups.

Asia-Pacific is the fastest-growing region, expected to log a 12.45% CAGR through 2031. China’s central government prioritises AI drug discovery under its latest Five-Year Plan, and Insilico Medicine secured USD 110 million Series E funding to expand Shanghai-based operations. Japan’s PMDA issued guidance that aligns with FDA model-validation tenets, streamlining dual submissions for global sponsors. Korea and Taiwan leverage robust electronic health-record penetration to furnish de-identified data for real-world model tuning. Overall, favourable reimbursement reforms and large treatment-naïve patient pools make the region an attractive site for hybrid trials that merge digital twins with streamlined physical arms.

Europe advances steadily, supported by the European Health Data Space initiative that will open anonymised registries across member states. Germany’s Medical Data Integration Center now connects 34 university hospitals, giving researchers access to a federated repository for cardiac, oncology and rare disease datasets. Sustainability and 3R ambitions add non-economic drivers; the Netherlands already mandates virtual evidence for high-risk device revisions when validated models exist. UK regulators, post-Brexit, pilot an agile review service for AI-augmented dossiers, aiming to recapture clinical-research leadership. Together these moves solidify Europe as the second-largest regional cluster for in-silico clinical trial adoption.

List of Companies Covered in this Report:

• Dassault Systemes
• Certara
• InSilicoTrials Technologies
• Novadiscovery
• Insilico Medicine
• Clarivate
• GNS Healthcare
• Immunetrics
• Evotec
• Abzena
• Simulation Plus
• Ansys
• Virtonomy
• Schrdinger
• Altair Engineering
• Physiomics Plc
• Voxel Pharma
• Concentra Analytics
• IBM Research (DeepQ)
• QSP Insights

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support